Embolic materials currently in use for portal vein embolization (PVE) do not treat the tumor, which poses a risk for tumor progression during the interval between PVE and surgical resection. Here, is developed an ionic-liquid-based embolic material (LEAD) for portal vein embolization, liver ablation, and drug delivery. LEAD is optimized and characterized for diffusivity, X-ray visibility, and cytotoxicity. In the porcine renal embolization model, LEAD delivered from the main renal artery reached vasculature down to 10 microns with uniform tissue ablation and delivery of small and large therapeutics. In non-survival and survival porcine experiments, successful PVE is achieved in minutes, leading to the expected chemical segmentectomy, and delivery of a large protein drug (i.e., Nivolumab) with LEAD. In cholangiocarcinoma mouse tumor models and in ex vivo human tumors, LEAD consistently achieved an effective ablation and wide drug distribution. Furthermore, various strains of drug-resistant patient-derived bacteria showed significant susceptibility to LEAD, suggesting that LEAD may also prevent infectious complications resulting from tissue ablation. With its capabilities to embolize, ablate, and deliver therapeutics, ease of use, and a high safety profile demonstrated in animal studies, LEAD offers a potential alternative to tumor ablation with or without PVE for FLR growth.

中文翻译：

---

用于快速门静脉栓塞、肝段切除术和胆管消融的导管导向离子液体栓塞剂

目前用于门静脉栓塞（PVE）的栓塞材料不能治疗肿瘤，这在 PVE 和手术切除之间存在肿瘤进展的风险。这里开发了一种基于离子液体的栓塞材料（LEAD），用于门静脉栓塞、肝脏消融和药物输送。 LEAD 针对扩散性、X 射线可见性和细胞毒性进行了优化和表征。在猪肾栓塞模型中，从主肾动脉输送的 LEAD 达到小至 10 微米的脉管系统，并均匀地消融组织并输送小型和大型治疗剂。在非存活和存活猪实验中，成功的 PVE 在几分钟内实现，导致预期的化学节段切除术，并用 LEAD 输送大蛋白药物（即 Nivolumab）。在胆管癌小鼠肿瘤模型和离体人类肿瘤中，LEAD 始终实现了有效的消融和广泛的药物分布。此外，各种耐药患者来源的细菌对 LEAD 表现出显着的敏感性，这表明 LEAD 还可以预防组织消融引起的感染性并发症。凭借其栓塞、消融和提供治疗的能力、易用性以及动物研究中证明的高安全性，LEAD 为有或没有 PVE 的肿瘤消融提供了一种潜在的替代方案，以促进 FLR 生长。